Nuclear Receptors in Drug Discovery and Development

Venue: Wyndham Newark

Location: Newark, New Jersey, United States

Event Date/Time: Jul 22, 2002 End Date/Time: Jul 23, 2002
Report as Spam

Description

AN EMERGING TARGET FAMILY WITH CROSS THERAPEUTIC APPLICATIONS




PRESENTATIONS BY:

Arqule Inc.
Bayer Corporation
Bristol-Myers Squibb
Cornell University
Eli Lilly & Company
Gene Networks Inc.
GlaxoSmithKline Research & Development
Karo Bio
Maxia Pharmaceuticals
National Cancer Institute
NICHD/NIH
NYU School of Medicine
Panvera Corporation
Pfizer Global R & D - La Jolla Labs
Structural GenomiX
Wyeth Pharmaceuticals
X-Ceptor Therapeutics


ORGANIZED INTO THREE SECTIONS:

1 - NUCLEAR RECEPTOR SIGNALING MECHANISMS
2 - METHODS FOR MEASURING NUCLEAR RECEPTOR ACTIVITIES
3 - DRUG DISCOVERY APPROACHES FOR SPECIFIC NUCLEAR RECEPTOR TARGET CLASSES





HIGHLIGHTS INCLUDE:

A Real Time Sensing Assay for Nuclear Receptor Ligands
NATIONAL CANCER INSTITUTE

Rational Development of Novel Nuclear Hormone Receptor Antagonists Through in silico Modeling Techniques
NEW YORK UNIVERSITY SCHOOL OF MEDICINE

Mechanisms Underlying Selective Coactivator Recognition by Nuclear Receptors
LILLY RESEARCH LABORATORIES

Measurement Of Ligand-Induced Conformational Changes In Nuclear Hormone Receptors Using Peptides From Phage Display Libraries
KARO BIO USA

The Peroxisome Proliferator-Activated Receptors: StructurEs and Drug Discovery
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT

Venue